Nuvectis Pharma (NVCT) said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage.
"The antitumor activity observed despite patients' advanced disease and extensive pre-treatment, while controlling for thrombocytopenia, is promising," said Ron Bentsur, CEO of Nuvectis.
The company expects to report additional clinical data from the trial in Q2 of next year, Bentsur said.
NXP800 was granted orphan drug designation by the US Food and Drug Administration in August.
Nuvectis Pharma shares were 54% lower in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。